New cocktail aims to shrink advanced kidney tumors
NCT ID NCT05501054
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining three drugs—ipilimumab, nivolumab, and ciforadenant—can better control advanced kidney cancer that has spread. About 50 adults with clear cell renal cell carcinoma who have not had prior treatment will receive the combo. The main goal is to see how many patients' tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ipilimumab, nivolumab, and ciforadenant
What this could lead to
If successful, this combination could offer a new first-line treatment option for advanced kidney cancer, potentially improving tumor shrinkage rates.
What could go wrong
This is an early-phase trial with only 50 participants, so results may not apply broadly. The three-drug combo may cause significant side effects, and it's unclear if it will outperform existing therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States